Electra Therapeutics, Inc. ETRA
IPO
NASDAQ
IPO Score
IPO Date
Sep 18, 2026
Recommendation
Dividend Power Score
Day's Range
$8.32$8.88
Latest Close
Volume
--
Avg Vol (90D)
--
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
Corporate Info
Website
Phone Number
(888) 743-2290
Address
230 E Grand Avenue
Suite S-100
South San Francisco, CA 94080
Suite S-100
South San Francisco, CA 94080
Country
United States
Year Founded
2018
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
46
Business Description
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.